Читать книгу Randomised Clinical Trials - David Machin - Страница 26

Erbel, Di Mario, Bartunek, et al. (2007) describe a non‐randomised multicentre trial involving 8 centres in which 63 patients were enrolled with single de novo lesions in a native coronary artery. In these patients, a total of 71 biodegradable magnesium stents were successfully implanted. The (composite) primary endpoint was the rate of major adverse cardiac events (MACE) defined as any one of: cardiac death, Q‐wave myocardial infarction or target lesion revascularisation at 4 months poststent implant. This was to be compared with an anticipated rate of 30%. They reported a rate of MACE at 4 months of 15/63 (23.8%); all of which were attributed to target lesion revascularisation (there were no deaths or Q‐wave myocardial infarctions) and concluded:

… biodegradable magnesium stents can achieve an immediate angiographic result similar to … other metal stents ….

Nevertheless, the authors also commented in their Discussion:

The absence of randomisation precludes direct comparison with other techniques of percutaneous revascularisation.

Key features include the following:

 Design: No comparison group hence non‐randomised, multicentre,

 Size: 71 stents in 63 patients,

 Endpoint: Composite endpoint – MACE,

 Analysis: Proportion experiencing MACE with 95% confidence interval,

 Conclusion: Bioabsorbable stents can achieve an immediate angiographic result similar to other metal stents and can be safely degraded.

The above examples of successfully completed clinical trials illustrate a wide range of topics investigated. These include patients with disease (breast cancer, colon cancer, eczema, glaucoma, malaria and diabetes mellitus), those requiring coronary artery stents or hand surgery, elderly residents of nursing homes, patients aged 25 years or more requiring at least two implant‐supported crowns for dental caries, healthy individuals and those requiring vaccinations. Although not included here, trials are conducted, for example, to evaluate different diagnostic procedures, different bed mattresses to reduce the incidence of bed sores, different dressings for wounds of all types and fertility regulation options for male and females of reproductive potential.

These trials are often termed Phase III trials in contrast with Phase I and Phase II trials which are concerned with early stages of the (often pharmaceutical) development process. Although the trials differ in aspects of their design, the majority have the general structure of a two (or more) group parallel design in which eligible patients are assigned to receive the alternative options (often treatments but more generally termed interventions) and then at some later time assessed in a way which will be indicative of (successful) outcome. The outcomes measured in these trials include the following: survival time, gastric emptying time, reduction in disease activity, visual field status, recurrent parasitaemia, major adverse cardiac events, pain, the number of hip fractures, systolic blood pressure and standard criteria used to assess dental restorations. In the trial of homoeopathic arnica for pain relief following hand surgery, assessment was made in a double‐blind or double‐masked manner in which neither the patient nor the assessor was aware of the specific treatment option actually received.

The methods used for the allocation to the options included simple randomisation of equal numbers per group, a 2 to 1 allocation; a minimisation procedure taking into account patient characteristics, randomisation to nursing homes (clusters) rather than to individual residents. For the split‐mouth design used for the comparing dental implants the authors’ state:

For randomization of the implant type, a pregenerated random sequence was created … . Opaque envelopes were sealed according to pregenerated list. An independent judge prepared all envelopes. … an assistant indicated which implant had to be placed first following the indications contained in the sequentially number envelope.

The non‐random allocation to a single‐arm study using a new bioabsorbable stent for coronary scaffolding might now be regarded as a feasibility study although the trial results were compared to that from historical data.

The trials ranged in size from 20 patients with colonic cancer to 5102 women with HER2‐positive breast cancer. One trial involved 522 eyes from 271 subjects another 88 single implant‐supported crowns teeth in 34 partially edentate patients. Although not fully detailed in the above summaries, methods of statistical analysis ranged from a simple comparison of two proportions to relatively complex methods using techniques for survival time outcomes.

In general, trials are designed to establish a difference between the (therapeutic) options under test and were one to exist. Consequently, they are sometimes termed superiority trials. However, in certain circumstances, as in the trial for the treatment of uncomplicated falciparum malaria, the research team were looking for non‐inferiority implying that the two treatment strategies of AQ + SP and AL would give very similar risks of failure. In the event, the trial suggested that AL was (unacceptably) less effective than AQ + SP implying that non‐inferiority was not established. Such designs usually imply that a satisfactory outcome is that the test treatment does not perform worse than the standard to an extent predefined by the investigating team. Thus, use of a non‐inferiority design often implies that, although some therapeutic loss may be conceded on the main outcome variable, other factors favouring the new therapy will have some features (gain) to offset this. For example, if the new compound was a little less effective (not equal to) but had a better toxicity profile, then this might be sufficient to prefer it for clinical practice.